Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP
about
sameAs
Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RSVIP/PACAP receptor mediation of cutaneous active vasodilation during heat stress in humansThe in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal arteryAnatomical and functional characterization of clock gene expression in neuroendocrine dopaminergic neurons.Molecular cloning and functional expression of a VIP-specific receptor.Vasoactive intestinal peptide fragment VIP10-28 and active vasodilation in human skin.Epac mediates PACAP-dependent long-term depression in the hippocampus.Caveolae-dependent internalization and homologous desensitization of VIP/PACAP receptor, VPAC₂, in gastrointestinal smooth muscleThe expression of vasoactive intestinal peptide receptor 1 is negatively modulated by microRNA 525-5p.Modulatory effects of vasoactive intestinal peptide on intestinal mucosal immunity and microbial community of weaned piglets challenged by an enterotoxigenic Escherichia coli (K88)Possible key residues that determine left gastric artery blood flow response to PACAP in dogs.Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review.Pituitary adenylate cyclase activating peptide (PACAP) participates in adipogenesis by activating ERK signaling pathway.Peripheral PACAP inhibits gastric acid secretion through somatostatin release in miceTargeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.PACAP38/PAC1 signaling induces bone marrow-derived cells homing to ischemic brain.GABA and Gi/o differentially control circadian rhythms and synchrony in clock neuronsEffect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome.Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.Structural and molecular conservation of glucagon-like Peptide-1 and its receptor confers selective ligand-receptor interaction.PKA-dependent activation of the vascular smooth muscle isoform of KATP channels by vasoactive intestinal polypeptide and its effect on relaxation of the mesenteric resistance arteryPituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells.Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluationMicroarray analyses of pituitary adenylate cyclase activating polypeptide (PACAP)-regulated gene targets in sympathetic neurons.CGRP and migraine: could PACAP play a role too?Differential activation of guinea pig intrinsic cardiac neurons by the PAC1 agonists maxadilan and pituitary adenylate cyclase-activating polypeptide 27 (PACAP27).Genomic biomarkers for molecular imaging: predicting the futureImmunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.Transcriptional modulation by VIP: a rational target against inflammatory disease.Headache and sleep: shared pathophysiological mechanisms.Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1.Backup Mechanisms Maintain PACAP/VIP-Induced Arterial Relaxations in Pituitary Adenylate Cyclase-Activating Polypeptide-Deficient Mice.Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine.Investigation of the possible functions of PACAP in human trophoblast cells.Pathophysiology of Migraine: A Disorder of Sensory Processing.Regulation of the cystic fibrosis transmembrane conductance regulator channel by beta-adrenergic agonists and vasoactive intestinal peptide in rat smooth muscle cells and its role in vasorelaxation.Activation of VPAC1 receptors by VIP and PACAP-27 in human bronchial epithelial cells induces CFTR-dependent chloride secretion.Fyn Signaling Is Compartmentalized to Dopamine D1 Receptor Expressing Neurons in the Dorsal Medial Striatum.Adenoviral transfer of vasoactive intestinal peptide (VIP) gene inhibits rat aortic and pulmonary artery smooth muscle cell proliferationInhibitory pathways in the circular muscle of rat jejunum.
P2860
Q24304303-EEE17956-B597-4795-A172-3318E4B83599Q24609073-233B7F16-7551-4C93-9919-C415BD951454Q28570985-76790679-795F-468B-8E50-AF9A5C557B48Q30445040-93E5BC5E-8114-4EED-B36C-6BFA62DE342FQ30823294-A2FAD59A-F158-480B-B493-F9C6C85A3E20Q33221964-F0C63606-BE33-4412-AFCD-CD62388CC1D3Q33383710-3EDF79D8-27C6-48B6-9DB9-9D14DCDCFC00Q33634673-E08E38D3-8D22-443D-A744-4A958016A086Q33656489-A0C1B68F-D29F-467E-9626-12510D6269EAQ34015572-E2440678-DEDA-43D6-B4CE-27911EB2C48EQ34200902-8F205C80-BE7F-4DDB-A513-CBD68553FC3DQ34961901-A9BB1B50-571B-41D7-A71B-0936C7369647Q34988506-68D7EF78-27E1-44E7-9442-C1A73E428269Q35047107-B6586C93-B1D5-4A15-96FA-3B916C106731Q35295564-5F3FFB96-574E-49D3-807E-B1ADBE6340A4Q35535637-AEC89499-B692-4E6D-B871-52AA33EB543DQ35539848-2CD8FEE8-C355-4B22-A5B1-A8F2542D731DQ35636782-96FC4CF2-4DD0-40E1-87F7-410DDF1478D7Q36153216-874A49C2-779A-4C1B-A176-9454485D8930Q36406906-FF5572BC-A921-40B1-B762-1BA00D77C35EQ36464471-325F7892-B446-4040-BAD2-746ABE533EFEQ36737168-D99449F6-B031-43A0-9FB2-86D08E0C13C5Q36983469-34E26E10-FBE6-4505-B7B5-748C0113C63EQ37348942-684D6D0B-324F-4614-B9CE-B462CD5A7902Q37384128-E0A2B4C7-DED3-4CCF-B11E-5BB7BFC07079Q37397262-0F2C948A-3FBC-4D5A-86EC-54CEA4A55FD4Q37508283-EE3FA684-C1A2-4E14-BFB4-110BADB6B9A3Q37552024-B16B0170-9B0D-4881-B55E-51133E9C67B5Q38019158-F76DD3D3-8975-440F-9174-B2BDBCB4BDFDQ38233014-30487D0C-B853-49F9-B36C-8793A44A9D32Q38319884-61CA25E7-B42F-41B8-8628-40C183BFFD0FQ38794015-BB3473A6-F9F6-49B7-BF62-41EFBFF81139Q38849190-993D82C7-C954-4050-8D13-F82A8E8EF67CQ38990442-1A9D429D-71C1-4E98-AB4D-192EED46884EQ39127073-0039BA02-107E-4E64-87C5-1C62720ABD43Q40578535-E4C55B7E-E854-4D00-A657-324CA767F48EQ40595358-26784954-C6A2-4805-A973-E1C2D5159BECQ41606015-1F45F28C-2F03-4813-9FCE-FB0D2BDF4E3FQ41810908-8CA6A82E-5EE0-4B43-A22D-18E099E9F907Q42183968-19D344BB-539F-4EC3-A365-DABF0287656A
P2860
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP
description
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2002
@ast
scientific article (publication date: 15 October 2002)
@en
vedecký článok (publikovaný 2002/10/15)
@sk
vědecký článek publikovaný v roce 2002
@cs
wetenschappelijk artikel (gepubliceerd op 2002/10/15)
@nl
наукова стаття, опублікована в жовтні 2002
@uk
مقالة علمية (نشرت في 15-10-2002)
@ar
name
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP
@ast
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP
@en
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP
@nl
type
label
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP
@ast
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP
@en
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP
@nl
prefLabel
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP
@ast
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP
@en
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP
@nl
P1433
P1476
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP
@en
P2093
M Laburthe
P304
P356
10.1016/S0167-0115(02)00099-X
P407
P577
2002-10-01T00:00:00Z